Please Wait
Applying Filters...
menu
    • menu
    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    LEBSA- Your strategic API source for niche molecules.

    Virtual Booth

    Contact Supplier

    Nuray is an expert in the synthesis of Niche novel APIs, the first to launch Generics, NCEs, Advanced Intermediates // USFDA certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-06

    Virtual Booth

    Contact Supplier

    Menu

    Obefazimod

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Abivax Enrolls 1st Patient In ENHANCE-CD Trial For Crohn's Disease
    Abivax Enrolls 1st Patient In ENHANCE-CD Trial For Crohn's Disease

    03 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/03/2958005/0/en/Abivax-Announces-First-Patient-Enrolled-in-ENHANCE-CD-the-Phase-2b-Trial-of-Obefazimod-in-Crohn-s-Disease.html

    GLOBENEWSWIRE
    03 Oct 2024
    Share Share
    Abivax: 25mg Obefazimod Shows 2-Year Success In Colitis Study
    Abivax: 25mg Obefazimod Shows 2-Year Success In Colitis Study

    03 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/03/2957449/0/en/Abivax-Reports-Positive-Interim-Efficacy-and-Safety-Analysis-of-Once-Daily-25mg-Obefazimod-in-Moderate-to-Severe-Ulcerative-Colitis-Patients-After-2-Years-of-Open-Label-Maintenance.html

    GLOBENEWSWIRE
    03 Oct 2024
    Share Share
    Abivax To Present Obefazimod Abstracts At UEG Week 2024
    Abivax To Present Obefazimod Abstracts At UEG Week 2024

    26 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/26/2953509/0/en/Abivax-to-Present-Three-Abstracts-for-Obefazimod-in-Ulcerative-Colitis-at-the-UEG-Week-2024.html

    GLOBENEWSWIRE
    26 Sep 2024
    Share Share
    Abivax Updates On UC Combination Therapy Program Strategy
    Abivax Updates On UC Combination Therapy Program Strategy

    25 Sep 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/09/25/2953338/0/en/Abivax-Provides-Update-on-Ulcerative-Colitis-UC-Combination-Therapy-Program-Strategy-and-Announces-Early-Preclinical-Combination-Data-of-Obefazimod-and-Etrasimod-in-Inflammatory-Bo.html

    GLOBENEWSWIRE
    25 Sep 2024
    Share Share
    Publication of an expert article in JCC on obefazimod as promising therapeutic
    Publication of an expert article in JCC on obefazimod as promising therapeutic

    02 May 2023

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2023-05-02/abivax-publication-of-an-expert-article-in-jcc-on-obefazimod-as-promising-therapeutic-management-op

    PHARMIWEB
    02 May 2023
    Share Share
    Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod
    Abivax Reports Two-Year Efficacy and Safety Data of Obefazimod

    17 Apr 2023

    // ACCESSWIRE

    https://www.accesswire.com/viewarticle.aspx?id=749561&lang=en

    ACCESSWIRE
    17 Apr 2023
    Share Share